Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
945 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01524783 | Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)(RADIANT-4) | completed | Phase 3 | 302 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 5, 2021 | clinicaltrials |
| NCT03326674 | Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC(CONTESSA) | terminated | Phase 3 | 685 | Odonate Therapeutics, Inc.INDUSTRY |
| 19 |
| Jul 30, 2021 |
| clinicaltrials |
| NCT03033511 | A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)(MERU) | terminated | Phase 3 | 748 | AbbVieINDUSTRY | 41 | Jul 29, 2021 | clinicaltrials |
| NCT02163759 | A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors(HIBISCUS I) | completed | Phase 3 | 358 | Hoffmann-La RocheINDUSTRY | 14 | Jul 23, 2021 | clinicaltrials |
| NCT02171429 | A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors(HIBISCUS II) | completed | Phase 3 | 358 | Hoffmann-La RocheINDUSTRY | 19 | Jul 23, 2021 | clinicaltrials |
| NCT01808573 | A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting(NALA) | completed | Phase 3 | 621 | Puma Biotechnology, Inc.INDUSTRY | 28 | Jun 11, 2021 | clinicaltrials |
| NCT01492101 | The BEACON Study (Breast Cancer Outcomes With NKTR-102)(BEACON) | completed | Phase 3 | 852 | Nektar TherapeuticsINDUSTRY | 11 | Jun 1, 2021 | clinicaltrials |
| NCT02218047 | AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.(CONTI-PV) | completed | Phase 3 | 170 | AOP Orphan Pharmaceuticals AGINDUSTRY | 12 | Jun 1, 2021 | clinicaltrials |
| NCT01100502 | A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) | completed | Phase 3 | 329 | Seagen Inc.INDUSTRY | 13 | May 14, 2021 | clinicaltrials |
| NCT01419665 | GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)(ASSIST_FL) | completed | Phase 3 | 629 | SandozINDUSTRY | 26 | May 14, 2021 | clinicaltrials |
| NCT01566721 | A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer(SafeHER) | completed | Phase 3 | 2,577 | Hoffmann-La RocheINDUSTRY | 59 | Apr 27, 2021 | clinicaltrials |
| NCT01865747 | A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma(METEOR) | completed | Phase 3 | 658 | ExelixisINDUSTRY | 26 | Apr 27, 2021 | clinicaltrials |
| NCT03296163 | A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)(STELLA) | completed | Phase 3 | 627 | mAbxience Research S.L.INDUSTRY | 18 | Apr 26, 2021 | clinicaltrials |
| NCT00704730 | Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer(EXAM) | completed | Phase 3 | 330 | ExelixisINDUSTRY | 24 | Apr 20, 2021 | clinicaltrials |
| NCT04393584 | FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma(RusGCG-01) | unknown | Phase 2 / Phase 3 | 538 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 13, 2021 | clinicaltrials |
| NCT01244191 | Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer | terminated | Phase 3 | 1,048 | Daiichi SankyoINDUSTRY | 23 | Apr 6, 2021 | clinicaltrials |
| NCT01763164 | Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma | completed | Phase 3 | 402 | PfizerINDUSTRY | 27 | Mar 22, 2021 | clinicaltrials |
| NCT00796445 | A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor | terminated | Phase 3 | 1,351 | GlaxoSmithKlineINDUSTRY | 32 | Mar 5, 2021 | clinicaltrials |
| NCT00073528 | Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer | completed | Phase 3 | 1,286 | Novartis PharmaceuticalsINDUSTRY | 29 | Feb 24, 2021 | clinicaltrials |
| NCT01597908 | Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma(COMBI-v) | completed | Phase 3 | 704 | Novartis PharmaceuticalsINDUSTRY | 28 | Feb 24, 2021 | clinicaltrials |
| NCT01584648 | A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma | completed | Phase 3 | 423 | Novartis PharmaceuticalsINDUSTRY | 14 | Feb 17, 2021 | clinicaltrials |
| NCT04753177 | The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer | unknown | Phase 2 / Phase 3 | 120 | Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology DispensaryOTHER | 1 | Feb 15, 2021 | clinicaltrials |
| NCT02369874 | Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer(EAGLE) | completed | Phase 3 | 736 | AstraZenecaINDUSTRY | 24 | Feb 10, 2021 | clinicaltrials |
| NCT04103697 | Neoadjuvant Chemotherapy in Patients With Intermediate Risk Upper and Mid Rectal Cancer(RuCorT-01) | unknown | Phase 3 | 560 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT04134897 | Neoadjuvant Chemotherapy in Patients With Moderate Risk Mid Rectal Cancer(RuCorT-02) | unknown | Phase 3 | 316 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT04135313 | Induction and Consolidation Chemotherapy in Patients With Locally Advanced CRM-positive Rectal Cancer(RuCorT-03) | unknown | Phase 3 | 540 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT03162796 | A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)(Discover-1) | completed | Phase 3 | 383 | Janssen Research & Development, LLCINDUSTRY | 13 | Feb 3, 2021 | clinicaltrials |
| NCT01774786 | A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer(JACOB) | completed | Phase 3 | 780 | Hoffmann-La RocheINDUSTRY | 32 | Dec 30, 2020 | clinicaltrials |
| NCT00480025 | GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer | terminated | Phase 3 | 2,278 | GlaxoSmithKlineINDUSTRY | 34 | Dec 22, 2020 | clinicaltrials |
| NCT03098030 | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 483 | United TherapeuticsINDUSTRY | 23 | Dec 9, 2020 | clinicaltrials |
| NCT02490488 | Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients | completed | Phase 2 / Phase 3 | 248 | AB ScienceINDUSTRY | 6 | Dec 8, 2020 | clinicaltrials |
| NCT03556956 | Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer | completed | Phase 2 / Phase 3 | 219 | AB ScienceINDUSTRY | 5 | Dec 8, 2020 | clinicaltrials |
| NCT03766295 | Masitinib Plus Gemcitabine in Pancreatic Cancer | completed | Phase 3 | 377 | AB ScienceINDUSTRY | 8 | Dec 8, 2020 | clinicaltrials |
| NCT00269828 | A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.(PIONEER) | terminated | Phase 3 | 600 | CTI BioPharmaINDUSTRY | 11 | Nov 24, 2020 | clinicaltrials |
| NCT01235962 | A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)(PROTECT) | completed | Phase 3 | 1,538 | Novartis PharmaceuticalsINDUSTRY | 26 | Nov 23, 2020 | clinicaltrials |
| NCT04000698 | Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias | unknown | Phase 3 | 25 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT00471497 | A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)(ENESTnd) | completed | Phase 3 | 846 | Novartis PharmaceuticalsINDUSTRY | 35 | Nov 18, 2020 | clinicaltrials |
| NCT01280565 | Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit | terminated | Phase 3 | 134 | AB ScienceINDUSTRY | 7 | Nov 5, 2020 | clinicaltrials |
| NCT00082433 | Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | completed | Phase 3 | 1,221 | R-PharmINDUSTRY | 29 | Nov 2, 2020 | clinicaltrials |
| NCT03288870 | Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)(DOMINUS) | unknown | Phase 2 / Phase 3 | 218 | BiocadINDUSTRY | 2 | Oct 29, 2020 | clinicaltrials |
| NCT00397345 | TroVax Renal Immunotherapy Survival Trial | completed | Phase 3 | 733 | Oxford BioMedicaINDUSTRY | 10 | Oct 19, 2020 | clinicaltrials |
| NCT02631876 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer(FORWARD I) | completed | Phase 3 | 366 | ImmunoGen, Inc.INDUSTRY | 13 | Oct 14, 2020 | clinicaltrials |
| NCT01076010 | An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301). | completed | Phase 3 | 277 | AVEO Pharmaceuticals, Inc.INDUSTRY | 15 | Oct 5, 2020 | clinicaltrials |
| NCT01773187 | Pacritinib Versus Best Available Therapy to Treat Myelofibrosis | terminated | Phase 3 | 327 | CTI BioPharmaINDUSTRY | 12 | Sep 29, 2020 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials